Abstract
Patients with β-thalassaemia major are susceptible to osteopenia due to several factors which interfere with bone remodeling. It is known that bone metabolism and skeletal consolidation result from a complex sequence of hormonal changes, where the concerted actions of GH, IGFI and sex hormones and their receptors, are responsible for the timing and attainment of skeletal consolidation. IGF-I and the corresponding binding protein (IGFBP-III), markers of bone metabolism and lumbar and femoral neck BMD were measured in 28 adult patients, undergoing hormonal replacement and chelation therapy and a hypertransfusion program, with β-thalassaemia major (12 males with mean age 22.5±3.1 and 16 females with mean age 27.5±8.2), and in 28 healthy volunteers matched for age, anthropometric features and sex to the patients. BMD values, both at lumbar and femoral neck level were significantly lower (p<0.001 and p<0.05) by 18.7 and 4.2% respectively, in patients than in the controls. Markers of bone resorption [pyridinoline (Pyr) 78.1±15.7 vs 47.5±11.2 pmol/μmol urinary creatinine, p<0.001 and deoxypyridinoline (D-Pyr) 21.9±3.5 vs 14.5±5.4 pmol/μmol urinary creatinine, p<0.001] were higher in patients than in controls, whereas the marker of bone formation was slightly lower [osteocalcin (BGP) 3.8±0.6 vs4.6±1.7 pmol/ml, p<0.05]. Plasma levels of IGF-I (21.07±5.12 vs 35.25±8.33 nmol/ml, p<0.001) and IGF binding protein III (IGFBP-III) (1.9±0.4 vs2.5±0.1 mg/ml, p<0.001) were lower in patients than in controls and positively correlated with BMD L2-L4 (r=0.57, p<0.05 and r=0.47, p<0.05 respectively), BMD neck (r=0.40, p<0.05 and r=0.34, p<0.05 respectively) and BGP (r=0.52, p<0.05 and r=0.34, p<0.05 respectively). Our β-thalassaemic patients, in spite of normalizing hemoglobin levels, adequate hormone replacement and chelation therapies, showed osteopenia and an unbalanced bone turnover with an increased resorptive phase and a decreased formation phase probably correlated to low levels of IGF-I and IGFBP-III observed in our study.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cooley T.B., Witwer E.R., Lee P. Anemia in children with splenomegaly and peculiar changes in bones. Am. J. Dis. Child. 1927, 34: 347–363.
Jensen C.E., Tuck S.M., Agnew J.E., et al. High prevalence of low bone mass in thalassaemia major. Br. J. Haematol. 1998, 103: 911–915.
Giardina P.J., Schneider R., Lesser M., et al. Abnormal bone metabolism in thalassaemia. In: Andò S., Brancati C., (Eds.), Endocrine Disorders in Thalassaemia. Springer Verlag, Berlin-Heidelberg, 1995, p. 39–46.
Cazzola M., De Stefano P., Porchio L., et al. Relationship between transfusion regimen and suppression of erythropiesis in beta-thalassemia major. Br. J. Haematol. 1995, 89: 473–478.
Wonke B., Jensen C., Hanslip J.J., et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J. Pediatr. Endocrinol. Metab. 1998, 11: 795–801.
El Hazmi M.A., Warsy A.S., Al Fawaz I. Iron-endocrine pattern in patients with β-thalassaemia. J. Trop. Pediatr. 1994, 40: 219–224.
Pratico G., Di Gregorio F., Caltabiano L., Palano G.M., Caruso-Nicoletti M. Calcium phosphate metabolism in thalassemia. Pediatr. Med. Chir. 1998, 20: 265–268.
Anapliotou M.L., Kastanias I.T., Psara P., Evangelou E.A., Liparaki M., Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin. Endocrinol. 1995, 42: 279–287.
Vullo C., De Sanctis V., Katz M., et al. Endocrine abnormalities in thalassaemia. Ann. NY. Acad. Sci. 1990, 612: 293–310.
Lasco A., Morabito N., Gaudio A., Buemi M., Wasniewska M., Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with β-thalassemia major. Osteoporos. Int. 2001, 12: 570–575.
Rechler M.M., Nissley S.P. Insulin-like growth factors. In: Sporn M.B., Roberts A.B. (Eds.) Peptide growth factors and their receptors. Springer-Verlag, Berlin-Heidelberg, 1990, p. 263–346.
Clemmons D.R. IGF Binding proteins: regulation of cellular actions. Growth Regul. 1992, 2: 80–87.
Working Party of the General Haematology Task Force of the British Committee for Standards in Haematology. The laboratory diagnosis of haemoglobinopathies. Br. J. Haematol. 1998, 101: 783–792.
De Vernejoul M.C., Girot R., Gueris J., et al. Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. J. Clin. Endocrinol. Metab. 1982, 54: 276–281.
Mohan S., Baylink D.J. Bone growth factors. Clin. Orthop. 1991, 263: 30–48.
Hayden J.M., Mohan S., Baylink D.J. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995, 17: 93S–98S.
Voskaridou E., Kyrtsonis M.C., Terpos E., et al. Bone resorption is increased in young adults with thalassaemia major. Br. J. Haematol. 2001, 112: 36–41.
Dresner Pollack R., Rachmilewitz E., Blumenfeld A., Idelson M., Goldfarb A.W. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br. J. Haematol. 2000, 111: 902–907.
Sartorio A., Conte G., Conti A., et al. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. J. Endocrinol. Invest. 2000, 23: 356–361.
Danesi L., Scacchi M., De Martin M., et al. Evaluation of hypothalamic-pituitary function in patients with thalassemia major. J. Endocrinol. Invest. 1992, 15: 177–184.
Pintor C., Cella S.G., Manso P., et al. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J. Clin. Endocrinol. Metab. 1986, 62: 263–267.
Leger J., Girot R., Crosnier H., Postel-Vinay M.C., Rappaport R. Normal growth hormone response to GH-releasing hormone in children with thalassemia major before puberty: a possible age related effect. J. Clin. Endocrinol. Metab. 1989, 69: 453–456.
Shehadeh N., Hazani A., Rudolf M.C., Peleg I., Benderly A., Hochberg Z. Neurosecretory dysfunction of growth hormone secretion in thalassemia major. Acta Paediatr. Scand. 1990, 79: 790–795.
Katzos G., Harsoulis F., Papadopoulou M., Athanasiou M., Sava K. Circadian growth hormone secretion in short multitrasfused prepubertal children with thalassemia major. Eur. J. Pediatr. 1995, 154: 445–449.
Chatterjee R., Katz M., Cox T., Bantock H. Evaluation of growth hormone in thalassemic boys with failed puberty: spontaneous versus provocative test. Eur. J. Pediatr. 1993, 152: 721–726.
Postel-Vinay M.C., Girot R., Leger J., et al. No evidence for a defect in growth hormone binding to liver membranes in thalassemia major. J. Clin. Endocrinol. Metab. 1989, 68: 94–98.
Chrysis D.C., Alexandrides T.K., Koromantzou E., et al. Novel application of IGF-I and IGFBP-III generation tests in the diagnosis of growth hormone axis disturbances in children with beta-thalassaemia. Clin. Endocrinol. (Oxf.) 2001, 54: 253–259.
Ross R.J. GH, IGF-I and binding proteins in altered nutritional states. Int. J. Obes. Relat. Metab. Disord. 2000, 24: S92–S95.
Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16: 3–34.
Schmid C., Steiner T., Froesch E.R. Insulin-like growth factor I supportsdifferentiation of cultered osteoblast like cells. FEBS Lett. 1984, 173: 48–52.
Hock J.M., Centrella M., Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 1988, 122: 254–260.
Ernst M., Froesch E.R. Growth hormone-dependent stimulation of osteoblast-like cells in serum free cultures via local synthesis of insulin-like growth factor I. Biochem. Biophys. Res. Commun. 1988, 151: 142–147.
Canalis E., McCarthy T., Centrella M. Isolation of growth factors from adult bovine bone. Calcif. Tissue Int. 1988, 43: 346–351.
Kream B.E., Petersen D.N., Raisz L.G. Cortisol enhances the anabolic effects of insulin-like growth factor I on collagen synthesis and procollagen messenger ribonucleic acid levels in cultered 21-day fetal rat calvariae. Endocrinology 1990, 126: 1576–1583.
Margolis R.N., Canalis E., Partridge N.C. Anabolic hormones in bone: basic research and therapeutic potential. J. Clin. Endocrinol. Metab. 1996, 81: 872–877.
Fiorelli G., Formigli L., Zecchi Orlandini S., et al. Characterization and function of the receptor for IGF-l in human preosteoclastic cells. Bone 1996, 18: 269–276.
Martin J.L., Baxter R.C. Insulin-like growth factor binding protein-3: biochemistry and physiology. Growth Regul. 1992, 2: 88–99.
Soliman A.T., EL Banna N., Abdel Fattah M., El Zalabani M.M., Ansari B.M. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998, 47: 541–548.
Wonke B. Bone disease in beta-thalassaemia major. Br. J. Haematol. 1998, 103: 897–901
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lasco, A., Morabito, N., Gaudio, A. et al. Osteoporosis and β-thalassemia major: Role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 25, 338–344 (2002). https://doi.org/10.1007/BF03344015
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344015